AML1/ETO阳性急性髓系白血病分子生物学特性的分析

Analysis of AML1/ETO Positive Acute Myeloid Leukemia Molecular Biolog-ical Characteristics

目的分析AML1/ETO阳性急性髓系白血病AML患者的分子生物学和临床特性,探讨治疗策略。方法方便选取该院于2011年12月—2016年12月收治的55例AML1/ETO阳性的AML患者的临床特征、形态学、免疫学、以及治疗、生存情况进行分析总结。结果 55例AML1/ETO阳性的AML患者中,白细胞大于10×109/L的30例(55%),髓外浸润9例(16%);14例表达CD19(25%),31例表达CD56(56%);46例患者进行了诱导化疗,首次化疗CR率为71.7%,二次化疗CR率94.2%,6例死亡;55例骨髓片均有异常中性中幼粒细胞;骨髓中异常中性中幼粒细胞比例(30.567±17.33)%大于原始粒细胞,而外周血中则原始粒细胞比例(16.10±13.35)%高于异常中性中幼粒细胞比例。结论 AML1/ETO阳性AML患者易并发高危因素,明确影响预后的因素,对指导临床治疗和改善AML1/ETO阳性AML患者的生存有重要的意义。

Objective To analyze the AML1/ETO positive acute myeloid leukemia molecular biological characteristics and study the treatment strategies. Methods Convenient selection 55 cases of AML patients with positive AML1/ETO admitted and treated in our hospital from December 2011 to December 2016 were selected and the clinical features, morphology and immunology, treatment and survival situations were analyzed and summarized. Results Of 55 cases, there were 30 cases whose leukocyte was more than 10×109/L(55%), 9 cases with extramedullary infiltration(16%), 14 cases with CD19 expression(25%) and 31 cases with CD56 expression(56%), and 46 cases underwent the induced chemotherapy, and the first chemotherapy CR rate and second chemotherapy CR rate were respectively 71.7% and 94.2%, and 6 cases died, and there were abnormal neutrophilic granulocytes in 55 cases of bone marrow smears, and the ratio of abnormal neutrophilic granulocytes in bones was(30.567±17.33)%, which was bigger than that of myeloblast, and the ratio of myeloblast ratio in the peripheral blood was(16.10±13.35)%, which was higher than that of abnormal neutrophilic granulocytes. Conclusion The AML patients with positive AML1/ETO are easy to be complicated by high-risk factors, and we should clear the prognosis influence factors, and it is of important significance to guiding the clinical treatment and improving the survival situation of them.